Literature DB >> 29634917

Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy.

Jessica Sabourin1, Angèle Boet2, Catherine Rucker-Martin2, Mélanie Lambert2, Ana-Maria Gomez1, Jean-Pierre Benitah1, Frédéric Perros2, Marc Humbert2, Fabrice Antigny3.   

Abstract

BACKGROUND: Right ventricular (RV) function is the most important prognostic factor for pulmonary arterial hypertension (PAH) patients. The progressive increase of pulmonary vascular resistance induces RV hypertrophy (RVH) and at term RV failure (RVF). However, the molecular mechanisms of RVH and RVF remain understudied. In this study, we gained insights into cytosolic Ca2+ signaling remodeling in ventricular cardiomyocytes during the pathogenesis of severe pulmonary hypertension (PH) induced in rats by monocrotaline (MCT) exposure, and we further identified molecular candidates responsible for this Ca2+ remodeling. METHODS AND
RESULTS: After PH induction, hypertrophied RV myocytes presented longer action potential duration, higher and faster [Ca2+]i transients and increased sarcoplasmic reticulum (SR) Ca2+ content, whereas no changes in these parameters were detected in left ventricular (LV) myocytes. These modifications were associated with increased P-Ser16-phospholamban pentamer expression without altering SERCA2a (Sarco/Endoplasmic Reticulum Ca2+-ATPase) pump abundance. Moreover, after PH induction, Ca2+ sparks frequency were higher in hypertrophied RV cells, while total RyR2 (Ryanodine Receptor) expression and phosphorylation were unaffected. Together with cellular hypertrophy, the T-tubules network was disorganized. Hypertrophied RV cardiomyocytes from MCT-exposed rats showed decreased expression of classical STIM1 (Stromal Interaction molecule) associated with increased expression of muscle-specific STIM1 Long isoform, glycosylated-Orai1 channel form, and TRPC1 and TRPC4 channels, which was correlated with an enhanced Ca2+-release-activated Ca2+ (CRAC)-like current. Pharmacological inhibition of TRPCs/Orai1 channels in hypertrophied RV cardiomyocytes normalized [Ca2+]i transients amplitude, the SR Ca2+ content and cell contractility to control levels. Finally, we showed that most of these changes did not appear in LV cardiomyocytes.
CONCLUSIONS: These new findings demonstrate RV-specific cellular Ca2+ cycling remodeling in PH rats with maladaptive RVH and that the STIM1L/Orai1/TRPC1/C4-dependent Ca2+ current participates in this Ca2+ remodeling in RVH secondary to PH.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Monocrotaline rat; Orai1; Pulmonary hypertension; Right ventricular hypertrophy; STIM1L; TRPCs; [Ca(2+)](i) transients

Mesh:

Substances:

Year:  2018        PMID: 29634917     DOI: 10.1016/j.yjmcc.2018.04.003

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  25 in total

Review 1.  TRPC1 as a negative regulator for TRPC4 and TRPC5 channels.

Authors:  Jinsung Kim; Juyeon Ko; Jongyun Myeong; Misun Kwak; Chansik Hong; Insuk So
Journal:  Pflugers Arch       Date:  2019-06-20       Impact factor: 3.657

Review 2.  STIM and Orai Mediated Regulation of Calcium Signaling in Age-Related Diseases.

Authors:  Helen E Collins; Dingguo Zhang; John C Chatham
Journal:  Front Aging       Date:  2022-04-19

3.  Distinct time courses and mechanics of right ventricular hypertrophy and diastolic stiffening in a male rat model of pulmonary arterial hypertension.

Authors:  Ethan D Kwan; Daniela Vélez-Rendón; Xiaoyan Zhang; Hao Mu; Megh Patel; Erica Pursell; Jennifer Stowe; Daniela Valdez-Jasso
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-08-27       Impact factor: 5.125

4.  Characterization of fibroblasts from hypertrophied right ventricle of pulmonary hypertensive rats.

Authors:  Keisuke Imoto; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Pflugers Arch       Date:  2018-06-02       Impact factor: 3.657

5.  Nanoscale Study of Calcium Handling Remodeling in Right Ventricular Cardiomyocytes Following Pulmonary Hypertension.

Authors:  Roman Medvedev; Jose L Sanchez-Alonso; Anita Alvarez-Laviada; Stefano Rossi; Eef Dries; Tilo Schorn; Vahitha B Abdul-Salam; Natalia Trayanova; Beata Wojciak-Stothard; Michele Miragoli; Giuseppe Faggian; Julia Gorelik
Journal:  Hypertension       Date:  2020-12-28       Impact factor: 10.190

6.  Myocardial Hypertrophy and Fibrosis Are Associated with Cardiomyocyte Beta-Catenin and TRPC6/Calcineurin/NFAT Signaling in Spontaneously Hypertensive Rats with 5/6 Nephrectomy.

Authors:  Evdokia Bogdanova; Olga Beresneva; Olga Galkina; Irina Zubina; Galina Ivanova; Marina Parastaeva; Natalia Semenova; Vladimir Dobronravov
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

7.  Pyridostigmine improves cardiac function and rhythmicity through RyR2 stabilization and inhibition of STIM1-mediated calcium entry in heart failure.

Authors:  Stephen Baine; Ingrid Bonilla; Andriy Belevych; Andrei Stepanov; Lisa E Dorn; Radmila Terentyeva; Dmitry Terentyev; Federica Accornero; Cynthia A Carnes; Sandor Gyorke
Journal:  J Cell Mol Med       Date:  2021-03-23       Impact factor: 5.310

Review 8.  SOCE in the cardiomyocyte: the secret is in the chambers.

Authors:  Paul Rosenberg; Hengtao Zhang; Victoria Graham Bryson; Chaojian Wang
Journal:  Pflugers Arch       Date:  2021-02-27       Impact factor: 3.657

9.  Calcium-induced calcium release in proximity to hair cell BK channels revealed by PKA activation.

Authors:  Jun-Ping Bai; Na Xue; Omolara Lawal; Anda Nyati; Joseph Santos-Sacchi; Dhasakumar Navaratnam
Journal:  Physiol Rep       Date:  2020-08

10.  Resveratrol Prevents Right Ventricle Dysfunction, Calcium Mishandling, and Energetic Failure via SIRT3 Stimulation in Pulmonary Arterial Hypertension.

Authors:  Judith Bernal-Ramírez; Christian Silva-Platas; Carlos Jerjes-Sánchez; Martín R Ramos-González; Eduardo Vázquez-Garza; Héctor Chapoy-Villanueva; Alicia Ramírez-Rivera; Ángel Zarain-Herzberg; Noemi García; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2021-06-20       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.